Abstract 63P
Background
Melatonin (MT) regulates sleep and antioxidants while interacting with our microbiota. Advances in technology allow a deeper understanding of our microbiome and its environment. Research is now focused on plant-derived molecules, including sulforaphane (SFN), known for activating antioxidant responses through the Nrf2 pathway and inhibiting NF-κB. This knowledge paves the way for new research and potential treatment strategies, highlighting the potential of plant-derived molecules.
Methods
Our study observed decreased melatonin levels in 52 cancer patients with severe dysbiosis. This group also had reduced Lactobacillus acidophilus and saccharomyces boulardii. By culturing these microorganisms and adding melatonin, we saw an enhanced expression of the myrosinase gene (TGG1), and strong antiproliferative effects on cancer cultures. Our findings highlight melatonin's potential role in modulating microorganism behavior and managing dysbiosis in cancer patients.
Results
Our study found low melatonin (MT) levels in cancer patients, linked to decreased Lactobacillus acidophilus and saccharomyces boulardii levels. MT exposure enhanced myrosinase gene expression and showed antiproliferative effects on cancer cultures. The use of NO synthase inhibitor reduced SFN yield, yet MT counteracted this effect. This emphasizes MT's potential role in SFN synthesis regulation and cancer disease initiation. Particularly, in cancer patients, decreased SFN biosynthesis due to deficiency of these microorganisms and dysbiosis may increase oxidative stress, initiating cancerous conditions.
Conclusions
This finding has implications for understanding SFN synthesis regulation by NO and H2O2. Importantly, in cancer patients with a lack of Lactobacillus acidophilus and saccharomyces boulardii and MT deficiency, there's an increased risk of oxidative stress, creating conditions conducive to cancer. Unresolved is whether MT deficiency precedes the failure of these microorganisms and myrosinase gene inhibition, or if these conditions result from deep dysbiosis leading to MT deficiency.
Editorial acknowledgement
Thanks so much of our consultants from Tbilisi State Medical University:
Professor Gaiane Simonia and Professor Nana Okrostsvaridze
Clinical trial identification
Legal entity responsible for the study
Tbilisi State Medical University and Institute for Personalized Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract